FDA panel to review Endo's oxymorphone ER for round-the-clock opioid treatment
This article was originally published in Scrip
Executive Summary
The US FDA's anesthetic and life support drugs advisory committee and the drug safety and risk management advisory committee will meet on 2 December to review an NDA from Endo Pharmaceuticals for oxymorphone HCl extended-release tablets, for an the proposed indication of relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.